Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389179 | 0.80 | KMT2A (0.44) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL29943265 | 0.80 | KMT2A (0.44) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL23389182 | 0.80 | KMT2A (0.44) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL23389232 | 0.79 | KMT2A (0.46) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL23389233 | 0.79 | KMT2A (0.46) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL29944026 | 0.75 | KMT2A (0.47) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL23389212 | 0.75 | KMT2A (0.47) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL23389209 | 0.75 | KMT2A (0.47) | KMT2AMEN1HRH4MAPTHRH3 | |
| SCHEMBL25991354 | 0.72 | HRH4 (0.51) | KMT2AMEN1HRH4HRH3AKR1C3 | |
| SCHEMBL25994295 | 0.71 | KMT2A (0.41) | KMT2AMEN1HRH4MAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885HRH4 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.